Signum Surgical develops the BioHealx™ implant, a helical, barbed bioabsorbable device designed to close anal fistulas by apposing tissue at the internal opening. This technology addresses the inadequacies of current treatments, which often result in slow healing, high rates of fecal incontinence, and the need for repeat surgeries.
Funding
$2.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current surgical treatments for anal fistulas often lead to slow healing, a high risk of fecal incontinence, and the need for repeated procedures, resulting in a poor quality of life for patients. Existing options are frequently ineffective in providing a lasting cure for this painful colorectal condition.
Solution
Signum Surgical's BioHealx™ implant offers a novel approach to anal fistula treatment by facilitating tissue apposition at the internal opening. The BioHealx™ is a helical, barbed, bioabsorbable implant designed for complete tissue enclosure post-delivery, thereby avoiding exposure to the ano-rectal canal. The implant is deployed using a pre-loaded, single-use delivery device that rotates the helical implant into the soft tissue surrounding the internal opening of the fistula. This method aims to address the limitations of existing treatments, promoting effective closure and healing of the fistula.
Target Audience
The primary target audience includes colorectal surgeons and hospitals seeking improved treatment options for patients suffering from anal fistulas.
Features
- Helical, barbed design to ensure secure tissue apposition.
- Bioabsorbable material for natural integration and elimination by the body.
- Single-use, pre-loaded delivery device for precise and sterile implantation.
- Minimally invasive procedure, reducing patient trauma and recovery time.
- Complete tissue enclosure to prevent exposure to the ano-rectal canal.